PBFT02

Passage Bio's PBFT02 demonstrated a durable increase in cerebrospinal fluid progranulin (PGRN) levels in FTD-GRN patients during the Phase 1/2 upliFT-D trial.

Passage Bio's PBFT02 gene therapy demonstrated robust and sustained increases in CSF progranulin levels in FTD-GRN patients in the upliFT-D trial.

Passage Bio's PBFT02 gene therapy demonstrated robust and sustained increases in CSF progranulin levels in FTD-GRN patients in the upliFT-D trial.

Passage Bio has received positive feedback from the FDA to expand its phase 1/2 upliFT-D clinical trial to include patients with frontotemporal dementia (FTD) due to C9orf72 mutations, following encouraging data from the trial's first cohort. The gene therapy PBFT02 aims to increase progranulin levels in the central nervous system, showing promising results in initial clinical data.

Passage Bio reports promising progress in its phase 1/2 clinical trial for a genetic form of FTD, with updated interim data showing elevated progranulin levels in patients. The company plans to dose a second cohort in 2024 and expects further data by 2025.